Company Profile

SCYNEXIS Stock Price, News & Catalysts

Ticker:
SCYX
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

2.60 USD (-7.62%)

Close

Last updated: November 19, 2026

50.6M USD

Market cap

Why the stock is moving

As of Nov 19, 2026, SCYX closed down 7.62% at $2.60. No new same-company headline was identified in the current news window.

Company overview

Metabolic Kidney-Disease Lead Program

SCYNEXIS is developing SCY-770, an orally administered, selective direct activator of AMPK acquired as PXL-770. The program is being advanced for autosomal dominant polycystic kidney disease, where AMPK activation may address multiple drivers of disease progression.

Antifungal Franchise

SCY-247 is the company's second-generation fungerp antifungal. It is being developed in oral and intravenous formulations for patients with serious fungal infections, including those with limited treatment options.

Small-Molecule Development Model

The company combines internally developed anti-infective expertise with acquired clinical assets, concentrating resources on differentiated small molecules with potential applications in both rare disease and hospital-based care.

BARDA-Supported Development

SCYNEXIS received a BARDA contract to support oral and intravenous SCY-247 development for invasive candidiasis. The award can fund multiple stages of the program if additional contract options are exercised.

Future catalysts

  • Initiation of the Phase 2 SCY-770 proof-of-concept study in ADPKD in the fourth quarter of 2026, with an interim analysis in the fourth quarter of 2027.
  • Initiation of Phase 2 development for oral and intravenous SCY-247 in 2027, subject to regulatory alignment.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of SCYNEXIS (SCYX)?

SCYNEXIS (SCYX) most recently closed at 2.60 USD, a -7.62% move versus the previous session.

What is the market cap of SCYNEXIS (SCYX)?

SCYNEXIS currently has a market capitalization of 50.6M USD on BioPharmSignal.

What does SCYNEXIS do?

Metabolic Kidney-Disease Lead Program SCYNEXIS is developing SCY-770, an orally administered, selective direct activator of AMPK acquired as PXL-770. The program is being advanced for autosomal dominant polycystic kidney disease, where AMPK activation may address multiple drivers of disease progression. Antifungal Franchise SCY-247 is the company's...

On which exchange is SCYX stock listed?

SCYNEXIS (SCYX) is associated with NASDAQ, United States, Biopharma.

What is SCY-770?

Initiation of the Phase 2 SCY-770 proof-of-concept study in ADPKD in the fourth quarter of 2026, with an interim analysis in the fourth quarter of 2027.

Which conditions is SCYNEXIS targeting with SCY-770?

SCYNEXIS is associated with rare disease, metabolic disease based on its company overview and current catalyst commentary.

How does SCYNEXIS describe recent progress with SCY-770?

Initiation of the Phase 2 SCY-770 proof-of-concept study in ADPKD in the fourth quarter of 2026, with an interim analysis in the fourth quarter of 2027.

What is PXL-770?

Metabolic Kidney-Disease Lead Program SCYNEXIS is developing SCY-770, an orally administered, selective direct activator of AMPK acquired as PXL-770.